PT  - JOURNAL ARTICLE
AU  - FERRIGNO, DOMENICO
AU  - BUCCHERI, GIANFRANCO
TI  - Weekly Chemotherapy with Cisplatin and Paclitaxel in Inoperable Non-small Cell Lung Cancer: An Extended Phase II Study
DP  - 2005 Nov 01
TA  - Anticancer Research
PG  - 4685--4692
VI  - 25
IP  - 6C
4099  - http://ar.iiarjournals.org/content/25/6C/4685.short
4100  - http://ar.iiarjournals.org/content/25/6C/4685.full
SO  - Anticancer Res2005 Nov 01; 25
AB  - Background: A phase II study of a cisplatin/paclitaxel combination given on a weekly schedule in the front-line treatment of non-small cell lung cancer (NSCLC) is reported. Patients and Methods: Treatment consisted of an intravenous infusion of cisplatin, 25 mg/m2, and paclitaxel, 80 mg/m2, every week. Chemotherapy was continued until completion of a 22-week treatment plan, disease progression, persistent toxicity, or patient refusal. Results: Seventy-nine patients entered the study. The median number of infusions per patient was 14 (range 0-22). The median dose-intensity was 75% of that projected. Toxicity was generally acceptable, and never life-threatening. Seven complete responses (pathologically documented in 4 patients) and 27 partial responses were observed for an overall response rate of 43%. The estimated median survival and median time to progression was 55 (95% CI: 38-71) and 37 weeks (95% CI: 31-44), respectively. Conclusion: In our experience, the weekly combination of cisplatin and paclitaxel is well tolerated, active and associated with remarkably long survivals. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved